EGFR and non-small cell lung carcinoma: Moreover, a phase III trial compared gefitinib and platinum-based doublets, and the results indicated that targeted therapy is superior to carboplatin-paclitaxel as an initial treatment for EGFR-positive NSCLC patients8.